111 related articles for article (PubMed ID: 2491287)
1. Modulation of macrophage functions by corynebacterium parvum preparations.
Bonina L; Delfino D; Costa GB; Arena A
Boll Ist Sieroter Milan; 1989; 68(1):62-6. PubMed ID: 2491287
[TBL] [Abstract][Full Text] [Related]
2. Impairment of macrophage antiviral activity by soluble tumor products. Effects of bacterial immunomodulators.
Bonina L; Arena A; Liberto MC; Iannello D; Merendino RA; Costa GB; Mastroeni P
G Batteriol Virol Immunol; 1988; 81(1-12):10-24. PubMed ID: 2856293
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of thermal response of normal and malignant tissues by Corynebacterium parvum.
Urano M; Yamashita T; Suit HD; Gerweck LE
Cancer Res; 1984 Jun; 44(6):2341-7. PubMed ID: 6722772
[TBL] [Abstract][Full Text] [Related]
4. Induction, maintenance, and reinduction of tumoricidal activity in bone marrow-derived mononuclear phagocytes by Corynebacterium parvum. Evidence for the involvement of a T cell- and interferon-gamma-independent pathway of macrophage activation.
Keller R; Keist R; Van der Meide PH; Groscurth P; Aguet M; Leist TP
J Immunol; 1987 Apr; 138(7):2366-71. PubMed ID: 3104463
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
[TBL] [Abstract][Full Text] [Related]
6. Effect of vaccine prepared from Corynebacterium parvum on the growth of Gardner lymphosarcoma in C3H strain mice.
Motycka K; Chudomel V; Bednár M; Bostík J
Arch Immunol Ther Exp (Warsz); 1984; 32(4):405-12. PubMed ID: 6549499
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of different strains of Corynebacterium parvum on natural cell-mediated cytotoxicity.
Nasrallah AG; Gallagher MT; Priest EL; Trentin JJ
Cancer Res; 1980 Nov; 40(11):4159-64. PubMed ID: 7471057
[TBL] [Abstract][Full Text] [Related]
8. The effect of nonspecific immune stimulation with Corynebacterium parvum and polidin on the Ehrlich ascites tumor growth.
Todoruţiu C; Rişcă R; Daicoviciu D; Mulea R
Morphol Embryol (Bucur); 1982; 28(1):77-83. PubMed ID: 6461826
[TBL] [Abstract][Full Text] [Related]
9. Mitogenicity of Corynebacterium parvum for mouse lymphocytes.
Zola H
Clin Exp Immunol; 1975 Dec; 22(3):514-21. PubMed ID: 817854
[TBL] [Abstract][Full Text] [Related]
10. Macrophage functions in beige (Chédiak-Higashi syndrome) mice.
Mahoney KH; Morse SS; Morahan PS
Cancer Res; 1980 Nov; 40(11):3934-9. PubMed ID: 7471044
[TBL] [Abstract][Full Text] [Related]
11. Protection by polyI:polyC against infection with herpes simplex virus in mice pretreated with Corynebacterium parvum.
Storch E; Baumgartl D; Kirchner H
Nat Immun Cell Growth Regul; 1983-1984; 3(3):134-42. PubMed ID: 6209572
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
Gusdon JP; Homesley HD; Jobson VW; Muss HB
Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus type 1 replication and IL-1 beta gene expression in mouse peritoneal macrophages activated in vivo by an attenuated Salmonella typhimurium vaccine or Corynebacterium parvum.
Wu L; Morahan PS; Hendrzak JA; Eisenstein TK
Microb Pathog; 1994 Jun; 16(6):387-99. PubMed ID: 7830526
[TBL] [Abstract][Full Text] [Related]
15. Studies on antitumor effect of corynebacterium parvum and pustulan on Lewis lung carcinoma in mice.
Budzyński W
Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):379-84. PubMed ID: 7184489
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cancer using Corynebacterium parvum: similarity of two preparations in four animal tumor models.
Bartlett GL; Kreider JW; Purnell DM
Cancer; 1980 Aug; 46(4):685-91. PubMed ID: 7397633
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the effectiveness and adverse effects of a Corynebacterium parvum vaccine made in Czechoslovakia with Coparvax, a British preparation made by Wellcome, in the treatment of malignant pleural effusions].
Marel M; Melínová L; Bednár M
Cas Lek Cesk; 1989 Aug; 128(34):1071-4. PubMed ID: 2790915
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors.
Ibraheim EH; El Kappany H; Nigam VN; Brailovsky CA; Madarnas P; Elhilali MM
Anticancer Res; 1984; 4(3):209-13. PubMed ID: 6465859
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of cancer with corynebacterium parvum.
Halpern B
Ann Allergy; 1978 Mar; 40(3):155-7. PubMed ID: 637374
[No Abstract] [Full Text] [Related]
20. Induction of resistance to ectromelia virus infection by corynebacterium parvum in murine peritoneal macrophages.
Cohen DA; Bubel HC
J Reticuloendothel Soc; 1983 Jan; 33(1):35-46. PubMed ID: 6300395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
